Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer by Dawn T Bravo et al.
Bravo et al. BMC Cancer 2013, 13:316
http://www.biomedcentral.com/1471-2407/13/316RESEARCH ARTICLE Open AccessFrizzled-8 receptor is activated by the Wnt-2
ligand in non-small cell lung cancer
Dawn T Bravo, Yi-Lin Yang, Kristopher Kuchenbecker, Ming-Szu Hung, Zhidong Xu, David M Jablons
and Liang You*Abstract
Background: Wnt-2 plays an oncogenic role in cancer, but which Frizzled receptor(s) mediates the Wnt-2 signaling
pathway in lung cancer remains unclear. We sought to (1) identify and evaluate the activation of Wnt-2 signaling
through Frizzled-8 in non-small cell lung cancer, and (2) test whether a novel expression construct dominant
negative Wnt-2 (dnhWnt-2) reduces tumor growth in a colony formation assay and in a xenograft mouse model.
Methods: Semi-quantitative RT-PCR was used to identify the expression of Wnt-2 and Frizzled-8 in 50 lung cancer
tissues from patients. The TCF reporter assay (TOP/FOP) was used to detect the activation of the Wnt canonical
pathway in vitro. A novel dnhWnt-2 construct was designed and used to inhibit activation of Wnt-2 signaling
through Frizzled-8 in 293T, 293, A549 and A427 cells and in a xenograft mouse model. Statistical comparisons were
made using Student’s t-test.
Results: Among the 50 lung cancer samples, we identified a 91% correlation between the transcriptional increase
of Wnt-2 and Frizzled-8 (p<0.05). The Wnt canonical pathway was activated when both Wnt-2 and Frizzled-8 were
co-expressed in 293T, 293, A549 and A427 cells. The dnhWnt-2 construct we used inhibited the activation of Wnt-2
signaling in 293T, 293, A549 and A427 cells, and reduced the colony formation of NSCLC cells when β-catenin was
present (p<0.05). Inhibition of Wnt-2 activation by the dnhWnt-2 construct further reduced the size and mass of
tumors in the xenograft mouse model (p<0.05). The inhibition also decreased the expression of target genes of
Wnt signaling in these tumors.
Conclusions: We demonstrated an activation of Wnt-2 signaling via the Frizzled-8 receptor in NSCLC cells. A novel
dnhWnt-2 construct significantly inhibits Wnt-2 signaling, reduces colony formation of NSCLC cells in vitro and
tumor growth in a xenograft mouse model. The dnhWnt-2 construct may provide a new therapeutic avenue for
targeting the Wnt pathway in lung cancer.
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Lung cancer is the most commonly diagnosed malig-
nancy worldwide and is responsible for over one million
deaths each year [1,2]. Current treatment strategies in-
clude surgical resection, chemotherapy, radiation ther-
apy, targeted therapy, or a combination of treatments,
depending on disease type and stage [1,2]. Despite ad-
vances in multimodality treatments, lung cancer remains* Correspondence: liang.you@ucsfmedctr.org
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reproduction in any medium, provided the orhighly lethal, with a 5-year survival rate of less than 15%
[2]. New treatment strategies are urgently needed.
Wnt signaling elicits numerous cellular responses in-
cluding self-renewals of stem cells [3]. Currently, 10
Frizzled proteins have been identified in mammals as
the receptors for Wnt proteins. Transduction of Wnt
signaling begins when Wnt ligands bind to the cysteine-
rich Wnt binding domain (CRD) of Frizzled receptors at
the cell membrane and initiate either the ‘canonical’
or ‘non-canonical’ pathways [4]. The canonical Wnt
signaling pathway regulates the stability of β-catenin
[5]. When Wnt is not activated, β-catenin is phos-
phorylated by the destruction complex and degradedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ceptors and low-density lipoprotein co-receptors 5 and 6
(LRP5/6) on cell membrane [8,9], Wnt signaling is acti-
vated and Dishevelled (DVL) recruits the destruction com-
plex to the plasma membrane [10], resulting in β-catenin
stabilization and subsequent accumulation in the cyto-
plasm [5]. Stabilized β-catenin then enters the cell nucleus
and associates with lymphoid enhancer-binding factor
(LEF)/T-cell factor (TCF) transcription factors [11,12] to
promote transcription of important downstream target
genes, many of which have been implicated in cancer
[13-15]. Aberrant activation caused by β-catenin or APC
mutations leads to the constitutive activation of Wnt ca-
nonical pathway in human colorectal cancers [16-19].
The Wnt pathway is aberrantly activated in numerous
cancers [20-22], including lung cancer [23,24]. Both
Wnt-1 and Wnt-2 are up-regulated in non-small cell
lung cancer (NSCLC) [25,26], whereas Wnt-7a is down-
regulated in most lung cancer cell lines and tumor tis-
sues [27]. Co-expression of both Wnt-7a and Fzd9 in-
hibits cell growth of NCSLC cell lines [27]. Moreover,
DVL has been shown to be over-expressed in 75% of
micro-dissected NSCLC tissues [28]. Approximately 85%
of all sporadic and hereditary colorectal tumors show
loss of APC function, resulting in stabilization of β-
catenin [29,30]. Mutations of the tumor suppressor gene
APC or β-catenin are rare in lung cancer [31,32] and the
Wnt pathway may be activated upstream of β-catenin
[32,33]. Furthermore, both sFRP1 and WIF1 genes are
reportedly silenced in lung cancer tissues [34-36]. Taken
together, these studies indicate the important roles of
the Wnt pathway in lung carcinogenesis.
Knowledge regarding the regulation of specific Wnts
and their corresponding receptors in lung cancer is lack-
ing. It is not known in great detail which receptors are
selectively expressed or the roles they play in the patho-
genesis of lung cancer. We recently found that Wnt-2
was upregulated in NSCLC [25]. Therefore, we sought
to build on this finding by investigating specific Wnt/
Frizzled interactions in human cancer cell lines and in
lung cancer tissue samples. We also examined whether a
dnhWnt-2 construct reduces tumor growth in cancer
cell lines and in a xenograft mouse model.
Methods
Cell lines and tissues
Human lung cancer cell lines A549 and A427 were
obtained from American Type Culture Collections
(ATCC) (Manassas, VA) and cultured in RPMI 1640
medium. Human kidney epithelial cell line 293 and
human kidney transfected epithelial cell line (293T)
were obtained from ATCC and cultured in Dulbecco’s
modified Eagle’s medium (DMEM). All cell cultures
were supplemented with 10% fetal bovine serum,penicillin (100 IU/ml), and streptomycin (100 μg/ml)
and incubated in a humid incubator with 5% CO2 at
37°C.
Fresh lung tumor tissues and adjacent normal lung
tissues from patients who underwent surgical resec-
tion for lung cancers were collected and snap-frozen
in liquid nitrogen in the operating room. Tissue
samples were kept at −170°C in a liquid nitrogen
freezer before use. The study was approved by the
Committee of Human Research at the University of
California and informed consent was obtained from
all patients.
Semi-quantitative RT-PCR and quantitative RT-PCR
Total RNA from mouse xenografts, fresh lung cancer
and paired adjacent normal tissue was extracted with
TRIzol LS (Invitrogen, Carlsbad, CA). Total RNA from
the various cell lines was isolated using Qiagen’s RNeasy
extraction method (Valencia, CA).
For semi-quantitative analysis, reverse transcription-
PCR was performed with 1 μg total RNA in a GeneAmp
PCR system 9700 (Applied Biosystems, Foster City, CA)
using SuperScript II One-step RT-PCR with Platinum
Taq (Invitrogen, Carlsbad, CA) for 25 cycles, according
to the manufacturer's instructions. Primers were
obtained from Operon Biotechnologies (Alameda, CA).
Primer sequences for the human Wnt-2 cDNA were 5′-
GGATGCCAGAGCCCTGATGAATCTT-3′ (Forward)
and 5′-GCCAGCCAGCATGTCCTGAGAGTA-3′ (re-
verse). Primers for the human Frizzled-8 cDNA were 5′
GGACTACAACCGCACCGACCT-3′ (forward), and 5′
ACCACAGGCCGATCCAGAAGAC-3′ (reverse). Pri-
mer sequences for human DVL-3, c-Myc, Cyclin D1 and
Survivin were obtained from Operon Biotechnologies.
The housekeeping gene glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) (5′ ATGGGGAAGGTGAAGGT
CGG-3′ forward; and 5′-GACGGTGCCATGGAATT
TGC-3′, reverse) was amplified as an internal control
[18,37]. The ratio of band intensity of Wnt-2 and
Frizzled-8 between fresh lung cancer and paired adjacent
normal tissues was measured using Image J software
(NIH, Bethesda, MD, USA).
For quantitative RT-PCR, first-strand cDNA was
synthesized from total RNA by iScript cDNA synthe-
sis (Bio-Rad, Hercules, CA) according to the manu-
facturer‘s instructions. Taqman RT-PCR analysis was
performed on cDNA in a 384-well plate using Prism
7900HT Real-Time PCR System (Applied Biosystems,
Foster City, CA). Primers and hybridization probes
for Wnt-2 and Frizzled-8 (inventoried, chosen from
the online catalog) were purchased from Applied
Biosystems (Foster City, CA). The expression of each
gene was assayed in triplicate and normalized to
GAPDH.
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The human Wnt-2 expression construct was kindly pro-
vided by J. Kitajewski (Columbia University). The
dominant-negative Wnt-2 construct was generated by
PCR amplification of the full-length human Wnt-2
cDNA using primers flanking the N-terminal domain
from residues 1–278. The amplified cDNA fragment was
then inserted into the pEGFP-N1vector (BD Biosciences
Clontech, Palo Alto, CA) upstream of the GFP epitope
to generate the dnhWnt-2 construct. The rat frizzled-1
(rFzd1), rFzd2; mouse frizzled-3 (mFzd3), mFzd4,
mFzd5, mFzd7, mFrizzled-8 and mFzd9 mammalian
expression constructs were kindly provided by R. Nusse
(Stanford University). The mFzd10 expression construct
was kindly provided by E. Morrisey (University of
Pennsylvania).
Selection for stable clones
Stable cell lines were generated by transfection of the ex-
pression vectors (pGFP-N1-dnhWnt-2) and control vec-
tor (pGFP-N1) into A549 and A427 cell lines using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according
to the manufacturer‘s instructions. Transfected cells were
selected by culturing in complete medium supplemented
with Geneticin at 400 μg/mL (Invitrogen) for approxi-
mately 1 month. The stable transfectants were isolated
and expanded for further analysis.
TOPflash assay
Luciferase assays for reporters were carried out using
the Dual-Luciferase Reporter Assay System (Promega,
Madison, WI) as reported previously [28]. Briefly, 293,
293T, A549 and A427 cell lines were plated in 96-well
plates with fresh media without antibiotics 24 hr before
transfection. Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) was used to mediate co-transfection of pTOPflash
(0.2 μg) or pFOPflash (0.2 μg) vectors (kindly provided
by H. Clevers, Netherlands Institute). The cell lines were
co-transfected with or without the following expression
constructs: Fzd, Wnt-2, dnhWnt-2 and empty vectors
pcDNA3.1 (Invitrogen) or pEGFP-N1 (each at 0.2 μg;
0.6 μg DNA in total), as indicated. The Renilla luciferase
reporter vector pRL-TK (0.02 μg) (Promega, Madison,
WI) was simultaneously transfected as the control for
transfection efficiency. TCF-mediated transcriptional ac-
tivity was determined by the ratio of pTOPflash/
pFOPflash luciferase activity, each normalized to the lu-
ciferase activities of the pRL-TK reporter. Cells were
harvested 48 hr after transfection. The experiments were
done in triplicate.
Western blot analysis
Whole cell lysates of cell lines were extracted with
CytoBuster Protein Extraction Reagent (Novagen, Madison,WI). Cytosolic proteins were prepared as previously
described [38]. The proteins were separated on 4–15%
gradient SDS–polyacrylamide gels and transferred to
Immobilon-P membranes (Millipore, Bellerica, MA). The
proteins were first bound with the following primary anti-
bodies: β-catenin (Transduction Laboratories, Lexington,
KY, USA) and β-actin (Sigma Chemical, St. Louis, MO).
Antigen-antibody complexes were detected by using an
ECL blotting analysis system (GE Healthcare Bio-Sciences,
Piscataway, NJ). The ratio of band intensity of β-catenin
to β-actin was measured using Image J software (NIH,
Bethesda, MD, USA).
Cell proliferation and colony formation assays
Cell proliferation was determined using the CellTiter
96 AQueous One Solution Cell Proliferation Assay
(Promega, Madison, WI). Briefly, A549 cells were
plated in a 6-well plate 24 hr before transfection.
Transient transfection was carried out using 4 μg of
the dnhWnt-2 construct or the pEGFP-N1 empty
vector. Twenty-four hours after transfection, cells
were seeded in a 96-well plate at a density of 5×102
cells per well and cultured for another 24 hr period
before the CellTiter 96 Aqueous One solution was
added. The assay was repeated daily for 4 consecu-
tive days. Cell viability was measured at absorbance
490 nm. Each experiment was done in triplicate and
repeated at least three times. Colony formation was
analyzed in stably transfected A549 and A427 cell
lines. Cells (5×102) were plated in 6-well cell-culture
dishes and incubated in complete medium containing
Geneticin (400 μg/mL) for a minimum of 14 days.
The colonies were then stained with 0.1% crystal
violet, and colonies were counted. Results were
shown as the mean number of colonies formed with
the presence of dnhWnt-2 or the empty vector con-
trol. Colony assays were performed a minimum of
three times each.
Tumor xenografts
All in vivo experiments were performed in accordance
with UCSF institutional guidelines (Institutional Animal
Care and Use Committee approval number: AN085516-
01). Six week-old female nude mice, strain athymic
Nu/Nu (Taconic, Hudson, NY) received subcutane-
ous injections of 5×106 cells in 100 μl of RPMI
1640, together with 25 μl of Matrigel basement
membrane matrix (Becton Dickinson, Bedford, MA).
Mice were inoculated subcutaneously into the right
flank with A549 stable clones expressing the
dnhWnt-2 vector and into the left flank with A549 cells
stably expressing the vector control. Tumors were mea-
sured twice weekly at their greatest length and width for
approximately 6 weeks. Tumor volume was calculated
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and was reported as the mean and standard deviation
(SD) of five independent measurements (n = 5 mice each).
After 43 days, tumors were resected and weighed. Total
RNA was extracted from tumor tissues for RT-PCR ana-
lysis. Immunostaining against Ki67 was done on formalin-
fixed, paraffin-embedded tumor specimens resected from
day 43 xenograft mice to access the level of cell prolifera-
tion. Briefly, antigen retrieval was achieved in citrate buf-
fer, and then blocked, followed by incubation with rabbit
monoclonal Ki67 antibody (Thermo Fisher Scientific Fre-
mont, CA). Sections were then incubated with secondary
goat anti-rabbit antibody (Vector Laboratories, INC. Bur-
lingame, CA) and counterstained with Hematoxylin. Ki67
proliferation was determined by the percentage of cells
with positive nuclear staining. Cell nuclei (2,500) were
counted on representative sections for each tumor type.
Statistical analysis
Statistical analysis was performed using GraphPad
Prism 6.0 for Windows. The values shown representFigure 1 Wnt-2 activation of Frizzled receptors. (A) TCF transcriptional
Frizzled expression vectors in the presence or absence of Wnt-2 cDNA and
and internal control plasmid pRL-TK. Experiments were performed in triplic
(TOP/FOP) (mean ± standard deviation). (B) Activation of Frizzled-8 by Wnt
was determined in the cells transfected with Frizzled-8, Wnt-2, both Frizzled
in triplicate.mean ± S.D. (error bars) of triplicate independent
experiments. The difference between groups was de-
termined by Student‘s t-tests and a p value ≤0.05
was considered statistically significant.
Results
Wnt-2 activation of frizzled receptors
Wnt-2 is overexpressed in multiple cancers [23], but the
specificity of the Wnt-2 interaction with its receptor(s)
remains largely unknown. We therefore investigated
Wnt-2 specificity by analyzing the abilities of several
Frizzled receptors to induce T cell factor (TCF)-
dependent transcription in the presence of Wnt-2. When
Wnt-2 was co-expressed with each of the Frizzled recep-
tors in 293T cells, TCF activity of Frizzled-8 increased by
at least 25 fold over that of vector alone (Figure 1A).
In addition, TCF activity of Fzd9 increased by ~15-
fold over that of vector control alone, affirming previously
reported data [39]. Frizzled-7 showed a 4-fold increase
in TCF-activity compared to vector control and
about a 2-fold increase due to the presence of Wnt-2.activity was measured in 293T cells transfected with the indicated
vector control. Cells were co-transfected with pTOPflash or pFOPflash
ate and the level of expression was shown as relative fold activation
-2 was measured in 293T, 293 and NSCLC cell line A549. TCF activity
-8 and Wnt-2, or vector control. Experiments were performed
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etc.) showed increased activation after Wnt-2 co-expression
(Figure 1A). We further analyzed this activation in
normal epithelial 293 cells and NSCLC cell line
A549. Wnt-2 activation of Frizzled-8 increased 5-fold
in these cell lines compared to that of vector con-
trol (p<0.01) (Figure 1B). The empty vector control
in A549 showed some activity, which is probably due
to the intrinsic Wnt signaling in this cancer cell line.
The results demonstrate for the first time that there
is an interaction between Wnt-2 and Frizzled-8 in
cancer cells.
Up-regulation of Wnt-2 and frizzled-8 in lung cancer
tissues
The lung cancer tissues analyzed comprised 36 pairs of
adenocarcinomas, 10 pairs of squamous cell carcinomas
and 4 pairs of large cell carcinomas. Semi-quantitative
RT-PCR analysis showed that Wnt-2 was up-regulated
by 70% and human Frizzled-8 was up-regulated by 42%
in the 50 lung tumor samples compared to their
matched normal tissue controls. Furthermore, among
the 21 lung tumor samples that had Frizzled-8 up-
regulation, 91% showed up-regulation of Wnt-2 (p<0.05)
(Figure 2).
Inhibition of Wnt-2 signaling by dnhWnt-2
We next sought to inhibit the effects of Wnt-2 activation
of Frizzled-8 by designing a novel dnhWnt-2 construct.
The human Wnt-2 gene was truncated at amino acidFigure 2 Up-regulation of Frizzled-8 and Wnt-2 in lung cancer. Semi-q
their corresponding matched, normal lung controls. Total RNA was reverse
The data shown are representative tumor pairs (tumor (T) and normal (N)).
gel. Experiments were performed in triplicate.position 278, resulting in an 82 residue carboxyl ter-
minal deletion generating the dnhWnt-2 construct. Co-
expression of the dnhWnt-2 construct together with
Wnt-2 and Frizzled-8 expression vectors in 293T and
293 cells strongly reduced TCF-dependent transcrip-
tional activity, as determined by the TOPflash assay
(Figure 3A). The 25-fold level of activation of
Frizzled-8 by Wnt-2 observed in 293T cells was re-
duced to near vector control levels. Similarly, activa-
tion of Frizzled-8 by Wnt-2 in the 293 cell line was
reduced. We further analyzed this activation in
NSCLC cell line A549, and observed a decrease of
TCF-dependent transcriptional activity by dnhWnt-2.
The dnhWnt-2 alone inhibited the intrinsic Wnt
(most likely Wnt-2) signaling and resulted in the low
background of TCF activity in A549 cell line (Figure 3A).
To determine if the dnhWnt-2 construct also affected β-
catenin stabilization, we analyzed cytosolic β-catenin pro-
tein levels (Figure 3B). In all cell lines, β-catenin protein
levels were elevated when cDNA of Frizzled-8 and Wnt-2
were co-expressed. However, dnhWnt-2 construct re-
duced cytosolic β-catenin protein levels to near back-
ground levels, even when Frizzled-8 and Wnt-2 were co-
expressed.
Effects of the dnhWnt-2 inhibitor in cancer cell lines
Since the dnhWnt-2 construct inhibited Wnt-2 signaling
mediated by the Frizzled-8 receptor, we further investi-
gated whether the dnhWnt-2 construct could inhibit
cancer cell growth. Quantitative real-time RT-PCRuantitative RT-PCR analysis of 50 freshly resected tumor samples with
transcribed and amplified with primers specific for Wnt-2 or Frizzled-8.
Semi-quantitative RT-PCR products were resolved on a 1.5% agarose
Figure 3 Dominant negative human Wnt-2 inhibits Frizzled-8 activation. (A) Inhibition of TCF transcriptional activity by dnhWnt-2 construct
was measured in 293T, 293 and A549 cells. In the present or absence of dnhWnt-2 construct, the cells were co-transfected with both Frizzled-8
and Wnt-2 expression vectors, either pTOPflash or pFOPflash, and internal control plasmid pRL-TK. Experiments were performed in triplicate. (B)
Stabilization of β-catenin by dnhWnt-2 expression in the indicated cell lines was determined by measuring cytosolic β-catenin protein levels in
the cells.
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overexpressed in NSCLC cell line A549 (Figure 4A)
compared to normal epithelial 293 and 293T cells. A cell
proliferation assay measured over a consecutive 4-day
period in A549 cells showed that dnhWnt-2 mutant
inhibited cell growth (Figure 4B). Wnt-2 was expressed
in NSCLC cell lines A549 and A427, which were stably
transfected with the dnhWnt-2 expression vector or the
vector control vector. When dnhWnt-2 was expressed,
the colony formation was reduced by 52% in the A549
cell line and was not affected in the A427 cell line
(Figure 5A, top). PCR primers, which are specific to
the sequence presented on both Wnt-2 and the
dnhWnt-2 construct, were used for semi-quantitative
RT-PCR analysis, and the expression of dnhWnt-2
and the endogenous Wnt-2 in A549 and A427 cells
was confirmed (Figure 5A, bottom). TCF-mediated
transcription was performed on the stable cell lines
(Figure 5B). A549 cells expressing the dnhWnt-2
gene showed a 36% decrease (p<0.02) in activity
compared to vector control cells. Based on our re-
sults, we have generated two hypothetical models.
Model of Wnt-2 signaling in A549 cells (Figure 5C)
shows that Wnt-2 binds to the Frizzled-8 receptor
and activates Wnt-2 signaling in A549 cells (Figure 5C,
left panel). The model also shows that dnhWnt-2 con-
struct completes the binding with Wnt-2, resulting in the
degradation of downstream β-catenin and the inhibitionof TCF activity in A549 cells (Figure 5C, right panel). A
model of Wnt-2 signaling in A427 cells (Figure 5D) shows
that β-catenin mutant constitutively activates downstream
Wnt signaling regardless of the presence of Wnt-2 ligand.
Xenograft mouse model
A xenograft mouse model was generated with A549 cells
stably expressing the dnhWnt-2 construct and vector
control plasmid. The cells were transplanted into female
athymic Nu/Nu mice and tumor formation was moni-
tored twice per week. Tumor size and mass decreased
significantly in the dnhWnt-2 tumors compared to
tumor controls (n = 5) after 43 days of growth (p<0.05)
(Figure 6A and 6B). Immunohistochemistry staining on
tumor sections with Ki67 demonstrated cell proliferation
at ~80% in control tumors compared to ~28% in
dnhWnt-2 tumors (>2000 cell counts) (Figure 6C). Fur-
ther analysis of the expression of Wnt downstream tar-
get genes in the dnhWnt-2 tumors (Figure 6D) showed
that the expression of Survivin, c-Myc, Dvl-3 and
Cyclin-D1 genes was down-regulated in dnhWnt-2 tu-
mors compared to control tumors.
Discussion
Wnt signaling is dysregulated in various tumors [21,22]
and Wnt-2 has been suggested to play an oncogenic role
in cancer [25,40]. Inhibition of Wnt signaling using dif-
ferent approaches has shown antitumor activity [22]. For
Figure 4 Endogenous expression levels of Wnt-2/Frizzled-8 and effects of dnhWnt-2 expression in normal epithelial cells and NSCLC
cells. (A) Endogenous expression levels of Wnt-2 and Frizzled-8 were determined by quantitative RT-PCR analysis in 293, 293T and A549 cells. (B)
Cell proliferation assays were performed in A549 cells transfected with dnhWnt-2 or vector control plasmids.
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2 signaling using siRNA induces programmed cell death
in NSCLC cells [25]. In the current study, we demon-
strated for the first time that Wnt-2 signaling is activated
through the Frizzled-8 receptor in NSCLC cells, and that
a novel dnhWnt-2 construct reduces tumor growth in
NSCLC cells and in a xenograft mouse model.
More recently, activation of Wnt signaling has been
implicated in the metastasis of human cancer. In lung
adenocarcinoma, activation of Wnt signaling has been
shown to be a determinant of metastasis to brain and
bone [41]. Moreover, enrichment of the Wnt-2 gene in
circulating tumor cells was identified using RNA se-
quencing [40]. The association of Wnt-2 up-regulation
with the formation of non-adherent tumors further sug-
gests that Wnt-2 regulates metastasis of adherent tu-
mors [40]. Our results suggest that therapeutic strategies
targeting Wnt-2 signaling may prevent the development
of metastasis and have potential impact on cancer
mortality.
A dominant negative Wnt-8 construct has been shown
to inhibit axis duplication induced by Wnt in the
Xenopus model [42]. In our study, the dnhWnt-2construct was designed by deleting an 82 amino acid
truncation in the carboxyl-terminal of the human
Wnt-2 gene. In our model, we demonstrated that
dnhWnt-2 construct competes for the binding to the
receptor(s) with Wnt-2, resulting in the degradation
of cytoslolic β-catenin and the inhibition of TCF
transcription in A549 cells (Figure 5C). In addition,
our data indicate that the presence of dnhWnt-2
construct decreased cell proliferation and colony for-
mation of A549 cells in vitro. We further analyzed
the effect of dnhWnt-2 construct in lung cancer cell line
A427, which harbors a mutation in the β-catenin gene
and constitutively activates the β-catenin mutant
(Figure 5D) [33]. As expected, dnhWnt-2 construct
had a minimal effect on Wnt-2 signaling and colony
formation in A427 cells. Although Wnt-2 is also
expressed in A427 cells, its canonical signaling is
probably more dependent on the β-catenin mutation
and less dependent on the upstream signaling by
Wnt ligands [43].
Although the frizzled family of receptors are known to
function as key components of the Wnt signaling pathway
[44], specific interactions of Wnt-2 with its receptor(s)
Figure 5 Effects of dnhWnt-2 expression in NSCLC cell lines. (A) Colony formation was determined in NSCLC cell lines A549 and A427.
Expression of dnhWnt-2 construct and endogenous Wnt-2 was detected using semi-quantitative RT-PCR in these cell lines. (B) TCF transcriptional
activity was measured in A549 and A427 cells in the present of dnhWnt-2 or vector control. Triplicate measurements were made and the level of
expression was shown as relative fold activation (TOP/FOP) (mean ± standard deviation). (C) Models of Wnt-2 signaling regulated in NSCLC cell
line A549. The Wnt canonical pathway is activated when endogenous Wnt-2 ligand (large triangle) binds to Frizzled-8 receptor (Fzd-8), which
recruits the intracellular protein disheveled (Dvl) to plasma membrane. Activation of Wnt canonical pathway prevents the phosphorylation of β-
catenin, resulting in the stabilization and translocation of β-catenin in the nucleus, where it activates target genes through binding to TCF
transcription factors. In the presence (+) of dnhWnt-2 construct (small triangle), endogenous Wnt-2 is prevented from binding to Frizzled-8
receptor. The activation of Wnt canonical pathway is inhibited, resulting in the degradation of β-catenin and blockage of TCF transcriptional
activity. (D) A model demonstrates Wnt-2 signaling regulation in NSCLC cell line A427, which harbors a β-catenin mutant (star). In A427 cells, the
dnhWnt-2 construct competes the binding of Frizzled-8 receptor with endogenous Wnt-2 and inhibits the activation of Wnt canonical pathway.
Instead of being phosphorylated and degraded, the β-catenin mutant is constitutively expressed and activates downstream Wnt signaling
regardless of the presence of Wnt-2- ligand.
Bravo et al. BMC Cancer 2013, 13:316 Page 8 of 11
http://www.biomedcentral.com/1471-2407/13/316have not been determined in lung cancer. In this
study, we investigated the activation of Wnt-2 signaling
through different Frizzled receptors. Our results
show that both Frizzled-8 and Frizzled-9 were acti-
vated when Wnt-2 signaling was present in 293T
cells. Overexpression of Frizzled-8 has been observed
in lung cancer tissues and cell lines [45], and inhi-
bition of Frizzled-8 expression using shRNA has
been shown to reduce the proliferation of tumorcells in vitro and in a xenograft mouse model [45].
Frizzled-8 has been suggested to regulate Wnt signaling in
lung cancer and can serve as a putative therapeutic target
for the disease [45]. Frizzled-9 has also been shown to play
a role in Wnt signaling. Rat Frizzled-9 receptor is acti-
vated by Wnt-2 and triggers the Wnt canonical pathway
in 293T cells [39], which is consistent with our observa-
tion. Frizzled-9 is also activated in Wnt-7a signaling and
functions as a tumor suppressor in lung cancer [27,46].
Figure 6 Tumor xenograft. (A) Tumor formation was monitored twice-weekly over a 43-day period in five groups of mice that received
subcutaneous injections of A549 cells, which express dnhWnt-2 or vector control expression constructs (mean ± standard deviation, p = 0.007).
(B) Tumor mass was measured on day 43 (mean ± standard deviation, p = 0.02). (C) Immunohistochemical analysis of cell proliferation by Ki-67
staining was performed in tumor sections expressing vector control (left panel) or the dnhWnt-2 (right panel) at 40× magnification. Inset is at
10× magnification. (D) qRT-PCR analysis of Wnt downstream target genes Survivin, c-Myc, DVL3, and Cyclin D1 in A549 xenograft tumors with
either dnhWnt-2 or vector control. Expression of GAPDH was used as a control transcript.
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signaling is to promote or suppress the development of
lung cancer is unknown. In addition to its role in onco-
genesis, Frizzled-9 mediates the activation of Wnt-7a sig-
naling in several developmental processes in normal tissue
[47-49]. The function of Frizzled-9 in Wnt signaling is
complex and its role in cancer development is not clear.
In addition, Wnt3a was shown to signal through multiple
Frizzled receptors in 293T cells [50], and Frizzled-5 ap-
pears to be the most active receptor for Wnt3a. In human
cancer, Wnt3a appears to function both as oncogene and
tumor suppressor gene in different cancer cell lines
[51,52]. Further studies are needed to investigate the role
of Wnt3a in lung cancer.
Inhibition of Wnt signaling has been shown to reduce
tumor growth in vitro and in mouse models using a var-
iety of approaches [25,47,53-58]. For instance, small
molecules have been used to inhibit Wnt secretion or
the transportation of β-catenin from the nucleus [47,55],
and siRNA has been used to inhibit Wnt-2 signaling and
induce apoptosis in NSCLC cells [25]. Fusion of
Frizzled-8 CRD to human Fc can function as a solublereceptor in vivo and has been shown to inhibit tumor
growth in xenograft models [59]. This antitumor activity
mediated by Frizzled-8 CRD could partially result from
the inhibition of Wnt-2 signaling. In this study, we used
the dnhWnt-2 construct as a novel approach against
lung cancer. Our results clearly show that the dnhWnt-2
construct reduces tumor growth in NSCLC cells and in
a xenograft mouse model. Together, our findings, and
those from other studies [25,59] strongly suggest that
the further development of dnhWnt-2 construct will be
useful in treating lung cancer.
Conclusions
Our study demonstrates a strong correlation between
the expression of Frizzled-8 and Wnt-2 in lung tumor
samples. A robust TCF-dependent transcriptional activa-
tion in cell lines was observed when both Wnt-2 and
Frizzled-8 are overexpressed. A novel dnhWnt-2 con-
struct was designed and used to inhibit TCF-mediated
transcription and colony formation when expressed in
NSCLC cell line A549. Moreover, the dnhWnt-2 con-
struct reduced tumor formation and the transcription of
Bravo et al. BMC Cancer 2013, 13:316 Page 10 of 11
http://www.biomedcentral.com/1471-2407/13/316downstream target genes in a xenograft mouse model.
Inhibition of Wnt-2 signaling with dnhWnt-2 construct
may provide a new therapeutic avenue for targeting the
Wnt pathway in lung cancer.
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